Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI6012 in Acute ST-Elevation Myocardial Infarction
2017-004521-32Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocardial infarction (MI) comparing MEDI6012 with Placebo (2 arms). Primary endpoint: Infarct size percentage of LV mass. Status: unknown.
02
Drugs
recombinant human lecithin-cholesterol acyltransferase
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2017-004521-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004521-32.